Anti-SARS-CoV-2 IgA Response in Baseline Seronegative and Seropositive Recipients of BNT162b2 mRNA COVID-19 Vaccine
| Errataetall: |
CommentOn: J Occup Environ Med. 2021 May 1;63(5):e314-e317. - PMID 33928943 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Journal of occupational and environmental medicine - 63(2021), 11 vom: 01. Nov., Seite e829 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salvagno, Gian Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BNT162 Vaccine |
|---|
| Anmerkungen: |
Date Completed 11.11.2021 Date Revised 18.08.2023 published: Print CommentOn: J Occup Environ Med. 2021 May 1;63(5):e314-e317. - PMID 33928943 Citation Status MEDLINE |
|---|
| doi: |
10.1097/JOM.0000000000002362 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329555537 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329555537 | ||
| 003 | DE-627 | ||
| 005 | 20231225205352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/JOM.0000000000002362 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM329555537 | ||
| 035 | |a (NLM)34412098 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salvagno, Gian Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-SARS-CoV-2 IgA Response in Baseline Seronegative and Seropositive Recipients of BNT162b2 mRNA COVID-19 Vaccine |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.11.2021 | ||
| 500 | |a Date Revised 18.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: J Occup Environ Med. 2021 May 1;63(5):e314-e317. - PMID 33928943 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Henry, Brandon M |e verfasserin |4 aut | |
| 700 | 1 | |a Lippi, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of occupational and environmental medicine |d 1998 |g 63(2021), 11 vom: 01. Nov., Seite e829 |w (DE-627)NLM075286661 |x 1536-5948 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2021 |g number:11 |g day:01 |g month:11 |g pages:e829 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/JOM.0000000000002362 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2021 |e 11 |b 01 |c 11 |h e829 | ||